Journal of Alzheimer's Disease 2016
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
Paraules clau
Resum
BACKGROUND
Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).
OBJECTIVE
To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
METHODS
Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
RESULTS
Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.
CONCLUSIONS
Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.
